ArticleInternational journal of molecular sciences2019
PGE
Abstract read
In one paragraph
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Modulation of Leukemic Blasts into Dendritic Cells (DCCancers · 2026Article
- Monitoring of (Leukemia-Specific) Immune Cells in Stages, Treatment Groups and in the Course of Disease and Therapy Contributes to Qualify Antileukemic Potential and Survival in Patients with AML.International journal of molecular sciences · 2025Article
- Dendritic Cells of Leukemic Origin (DCCancers · 2025Article
- Article
- Leukemia-Derived Dendritic Cells Induce Anti-Leukemic Effects Ex Vivo in AML Independently of Patients' Clinical and Biological Features.International journal of molecular sciences · 2025Article
- In Vivo Induction of Leukemia-Specific Adaptive and Innate Immune Cells by Treatment of AML-Diseased Rats and Therapy-Refractory AML Patients with Blast Modulating Response Modifiers.International journal of molecular sciences · 2024Article
- Article
- Effective and Successful Quantification of Leukemia-Specific Immune Cells in AML Patients' Blood or Culture, Focusing on Intracellular Cytokine and Degranulation Assays.International journal of molecular sciences · 2024Article
- Concentration-dependent effects of immunomodulatory cocktails on the generation of leukemia-derived dendritic cells, DCFrontiers in immunology · 2024Article
- Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients' Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture.International journal of molecular sciences · 2023Article
- Volatile Phases Derived from Serum, DC, or MLC Culture Supernatants to Deduce a VOC-Based Diagnostic Profiling Strategy for Leukemic Diseases.Biomolecules · 2023Article
- The potential role of serum extracellular vesicle derived small RNAs in AML research as non-invasive biomarker.Nanoscale advances · 2023Article
- Leukemic conversion involvingFrontiers in oncology · 2023Article
- Anti-platelet aggregation activities of different grades ofFrontiers in pharmacology · 2023Article
- Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes.International journal of molecular sciences · 2022Article
- Generation of Leukaemia-Derived Dendritic Cells (DCInternational journal of molecular sciences · 2022Article
- Interferon Gamma Secretion of Adaptive and Innate Immune Cells as a Parameter to Describe Leukaemia-Derived Dendritic-Cell-Mediated Immune Responses in Acute Myeloid Leukaemia in vitro.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Article
- Research progress on dendritic cell vaccines in cancer immunotherapy.Experimental hematology & oncology · 2022Review
- Targeting lipid metabolism reprogramming of immunocytes in response to the tumor microenvironment stressor: A potential approach for tumor therapy.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Daniel Christoph AmbergerMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. daniel.amberger@gmx.at.
Fatemeh Doraneh-GardMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. nikoo_792000@yahoo.com.
Carina GunsiliusMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. Carina_Gunsilius@web.de.
Melanie WeinmannMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. melli.weinmann@hotmail.de.
Sabine MöbiusMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. sabine.moebius@tum.de.
Christoph KuglerMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. christophkugler@gmx.net.
Nicole RogersMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. nicimunrog@yahoo.de.ORCID 0000-0002-7882-6334
Corinna BöckMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. corinna.boeck@uk-erlangen.de.
Uwe KödelDepartment of Neurology, Klinikum Großhadern, Ludwig-Maximilians-University, 81377 Munich, Germany. Uwe.Koedel@med.uni-muenchen.de.ORCID 0000-0002-2666-0731
Jan-Ole WernerDepartment of Hematology and Oncology, University Hospital of Tuebingen, 72076 Tuebingen, Germany. Jan-ole.werner@klinikum-nuernberg.de.
Doris KrämerDepartment for Hematology and Oncology, University Hospital of Oldenburg, 26133 Oldenburg, Germany. onko.med@bhv.ameos.de.
Britta Eiz-VesperInstitute for Transfusion Medicine, Hannover Medical School, 30625 Hannover, Germany. Eiz-Vesper.Britta@mh-hannover.de.
Andreas RankDepartment of Hematology and Oncology, University Hospital of Augsburg, 86156 Augsburg, Germany. andreas.rank@klinikum-augsburg.de.
Christoph SchmidDepartment of Hematology and Oncology, University Hospital of Augsburg, 86156 Augsburg, Germany. christoph.schmid@klinikum-augsburg.de.
Helga Maria SchmetzerMedical Department 3, Working-group: Immune-Modulation, University Hospital Munich, 81377 Munich, Germany. Helga.Schmetzer@med.uni-muenchen.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dendritic cells (DCs) and leukemia-derived DC (DC
Indexed as
AdultAgedAlprostadilBiomarkersCell DifferentiationCytokinesDendritic CellsFemaleFlow CytometryHumansImmunomodulationImmunophenotypingLeukemia, Myeloid, AcuteLeukocytes, MononuclearMaleMiddle AgedAlprostadilBiomarkersCytokinesPicibanilAMLdendritic cellsimmunotherapyleukemia-derived dendritic cellsPGE1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.